Claims

1. Liquid pharmaceutical composition comprising a polypeptide, TRIS and phosphate, the polypeptide comprising the amino acid sequence reproduced in SEQ ID NO: 8, characterized in

that the composition contains the polypeptide in a concentration of from 0.5 µg/ml to 3.0 mg/ml,

that the composition contains 100 mM TRIS and 50 mM phosphate,

that the pH of the composition is about 6.0 and

that the composition contains 0.04% polysorbate 80.

2. Composition according to Claim 1, characterized in that the composition additionally contains a lyoprotectant.

3. Composition according to Claim 2, characterized in that the composition contains 2 - 10% of a lyoprotectant.

4. Composition according to either of Claims 2 and 3, characterized in that the lyoprotectant is trehalose or trehalose dihydrate.

5. Composition according to Claim 1, characterized in that the composition additionally contains about 4% trehalose dihydrate.

6. Composition according to any of the preceding claims, characterized in that the composition contains the polypeptide in a concentration of 2 mg/ml.

7. Solids mixture obtainable by lyophilization of a liquid composition according to any of the preceding claims.

8. Liquid pharmaceutical composition, characterized in that the composition is reconstituted by dissolving a lyophilized solids mixture according to claim 6 in a suitable liquid medium.

9. Composition according to any of the preceding claims, characterized in that the bioavailability of the polypeptide following subcutaneous administration of the composition is >60%.

10. Composition according to any of the preceding claims for use in therapy.

11. Composition according to any of the preceding claims for use in therapy, said therapy comprising parenteral administration of the composition.

12. Composition according to any of the preceding claims for use in the treatment of hyper-proliferative diseases of the prostate.

13. Composition according to any of the preceding claims for use in the treatment of hyper-proliferative diseases of the prostate, the treatment comprising subcutaneous administration of the composition.

14. Syringe containing a composition according to any of the preceding claims.

Claims

1. Liquid pharmaceutical composition comprising a polypeptide, TRIS and phosphate, the polypeptide comprising the amino acid sequence reproduced in SEQ ID NO: 8, characterized in

   that the composition contains the polypeptide in a concentration of from 0.5 µg/ml to 3.0 mg/ml,

   that the composition contains 100 mM TRIS and 50 mM phosphate,

   that the pH of the composition is about 6.0,

   that the composition contains 0.04% polysorbate 80 and

   that the composition contains a lyoprotectant.

2. Composition according to Claim 1, characterized in that the composition contains 2 - 10% of a lyoprotectant.

3. Composition according to either of Claims 1 and 2, characterized in that the lyoprotectant is trehalose or trehalose dihydrate.

4. Composition according to any of the preceding claims, characterized in that the composition contains the polypeptide in a concentration of 2 mg/ml.

5. Solids mixture obtainable by lyophilization of a liquid composition according to any of the preceding claims.

6. Liquid pharmaceutical composition, characterized in that the composition is reconstituted by dissolving a lyophilized solids mixture according to claim 5 in a suitable liquid medium.

7. Composition according to any of the preceding claims, characterized in that the bioavailability of the polypeptide following subcutaneous administration of the composition is >60%.

8. Composition according to any of the preceding claims for use in a therapy.

9. Composition according to any of the preceding claims for use in a therapy, said therapy comprising parenteral administration of the composition.

10. Composition according to any of the preceding claims for use in the treatment of hyper-proliferative diseases of the prostate.

11. Composition according to any of the preceding claims for use in the treatment of hyper-proliferative diseases of the prostate, the treatment comprising subcutaneous administration of the composition.

12. Syringe containing a composition according to any of the preceding claims.